ASSAN

Anti-human DDR1 Antibody mIgG2a


Catalog Number Product Size Price
A1029-100 Anti-human DDR1 Antibody mIgG2a 100µg $185 Order
A1029-200 Anti-human DDR1 Antibody mIgG2a 200µg $325 Order
A1029-500 Anti-human DDR1 Antibody mIgG2a 500µg $545 Order

Product Specifications


Catalog Number A1029
Product Name Anti-human DDR1 antibody, mIgG2a
Source Derive from mouse hybridoma, mouse immunized with human DDR1 extra cellular domain
Clone Z8BS4
Species Reactivity Human
Isotype Mouse IgG2a
Purity >95%
Formulation 1x PBS, pH 6.8; Sterile
Stability & Storage 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw
Protein Aggregation Not obvious on SDS-PAGE
Application Flow cytometry, ELISA, cell-based assay
Product Datasheet: Download PDF

Representative Data


A. Flow cytometry

Detection of human DDR1 on Human DDR1-CHO-K1 cells (Cat.#C3030) by flow cytometry. Anti-human DDR1 antibody Z8BS4 (Cat.#A1029) was incubated with human DDR1-CHO-K1 cells (Cat.#C3030), followed by staining with PE-anti-mouse IgG.

B. SDS-PAGE analysis of anti-human DDR1 Z8BS4 (Cat.#A1029)






Background


DDR1 (discoidin domain receptor tyrosine kinase 1), also known as CD167, CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, EDDR1, MCK10, NTRK4, and PTK3A, is a receptor tyrosine kinase (RTK) and belongs to a subfamily of tyrosine kinase receptors with a homology region to the Dictyosteliumdiscoideum protein discoidin I in its extracellular domain. DDR1 consists of three regions (an extracellular ligand binding domain, a transmembrane domain, and an intracellular region containing a kinase domain), with its kinase activity induced by receptor-specific ligand binding. Collagen binding to DDR1 stimulates its autophosphorylation, activating kinase activity and signaling to downstream signaling pathways. DDR1 expression is restricted to epithelial cells, particularly in the kidney, lung, gastrointestinal tract, and brain and is significantly over-expressed in several human tumors from breast, ovarian, esophageal, and brain. DDR1 plays a key role in the development and progression of breast and ovarian cancer and is a promising therapeutic target.

References

Johnson, J. D., Edman, J. C., Rutter, W. J., Proc. Nat. Acad. Sci. 90: 5677-5681, 1993.
Chen, L., et al, Frontiers in Cell and Dev. Bio. 9: 747314, 2021.
Letinger, B., Int Rev Cell Mol Biol., 310: 39-87, 2014.
Vogel, W., et al., Mol. Cell, 1: 13–23, 1997.